Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 3-Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

      Headlines

      Mon, 22 Dec 2014

      cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc 's treatments after trying for nearly a year to win a deeper discount.

    2. RPT-UPDATE 2-Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

      Headlines

      Mon, 22 Dec 2014

      cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc 's treatments after trying for nearly a year to win a deeper discount.

    3. Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment

      Headlines

      Mon, 22 Dec 2014

      Dec 22 (Reuters) - The nation's largest pharmacy benefit manager has lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc treatments, Express Scripts said on Monday.

    4. AbbVie says newly approved hepatitis C treatment costs $83,319

      Headlines

      Fri, 19 Dec 2014

      Dec 19 (Reuters) - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc .

    5. UPDATE 1-U.S. FDA approves AbbVie all-oral hepatitis C treatment

      Headlines

      Fri, 19 Dec 2014

      Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for...

    6. U.S. FDA approves AbbVie all-oral hepatitis C treatment

      Headlines

      Fri, 19 Dec 2014

      Dec 19 (Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for...

    7. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

      Headlines

      Tue, 16 Dec 2014

      names during the year, including Applied Materials AMAT "> AMAT , Iron Mountain IRM "> IRM , Apple, and Gilead Sciences GILD "> GILD . Even so, its year-to-date performance is only marginally better than the performance of the S&P 500

    8. From Barron’s, December 15, 2014 (Part 2)

      Commentary

      Sat, 13 Dec 2014

      investorsentimentreadings.html Bullish stories: Carnival & Royal Caribbean Cruises [ CCL; RCL ; pg 21]; FMC [pg 23; see link below]; Gilead [ GILD ; pg 25]; Korean steel maker Posco [ PKX ; pg 25]; Nestle [NESN.sw/ NSRGY ; CEO spotlight on Paul Bulcke ; pg 56

    9. Gilead sued over 'exorbitant' hepatitis C drug prices

      Headlines

      Wed, 10 Dec 2014

      Dec 10 (Reuters) - Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi.

    10. Gilead's Shot in the Arm

      Video Reports

      Wed, 10 Dec 2014

      benefit of shareholder value. Gilead Sciences ' ( GILD ) CEO John Martin has done a fantastic ..... than 100-fold. As a result of Gilead 's strong capital-allocation ..... analyst Karen Andersen, who covers Gilead full time, thought this was a

      Gilead Sciences found at 0:16

      very good job of allocating capital for the benefit of shareholder value. Gilead Sciences' ( GILD ) CEO John Martin has done a fantastic job doing this since 1996. Since he took over the role in that year, the stock is up more than 100-fold. As a result of Gilead's strong capital-allocation strategy, one of the acquisitions that they have made in recent years that has done very, very well for shareholders is the 2012 acquisition of Pharmasset. Senior analyst Karen Andersen, who covers Gilead full time, thought this was a very strong acquisition. She thinks that the company's return on invested capital could reach the mid-20%
    « Prev12345Next »
    Content Partners